Radiopharm Theranostics reports 93% trial success
Radiopharm Theranostics (ASX:RAD) reported positive Phase 2b trial results for RAD 101, showing 93% image concordance in brain metastasis patients.
Todas as matérias desta categoria, das mais recentes às mais antigas.
Radiopharm Theranostics (ASX:RAD) reported positive Phase 2b trial results for RAD 101, showing 93% image concordance in brain metastasis patients.
Lumos Diagnostics (ASX:LDX) secured a FebriDx rollout across 30 US urgent care sites handling 200,000 annual patient visits.
Pharmaceutical manufacturer IDT Australia (ASX:IDT) upgraded its financial year 2026 revenue guidance to $16.8 million.
Healthcare technology company Beamtree (ASX:BMT) announced CFO Michelle Spiller will resign effective July 24.
Telix Pharmaceuticals (ASX:TLX) generated US$247 million in group revenue for the second quarter ended June 30.
Entropy Neurodynamics (ASX:ENP) secured a South African patent for psilocybin-based fibromyalgia treatments.
Medical device developer PainChek (ASX:PCK) has appointed Karen Holzberger as CEO, effective Aug. 17.
Neurizon Therapeutics (ASX:NUZ) has finished participant enrolment for Regimen I of the HEALEY ALS Platform Trial.
LTR Pharma (ASX:LTP) has executed a definitive telehealth distribution agreement with U.S. platform Shed Holdings.
Dimerix (ASX:DXB) secured an $10 million non-dilutive loan facility with SKIPTAN to fund its Phase 3 clinical trials.
Mayne Pharma (ASX:MYX) appointed Griffin D. Buchanan as CFO, effective Aug. 1.
Argenica Therapeutics (ASX:AGN) reports positive preclinical data as lead drug ARG-007 reduces concussion damage.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade